Background: Treg based immunotherapy is of great interest to facilitate tolerance in autoimmunity and transplantation. For clinical trials, it is essential to have a clinical grade Treg isolation protocol in accordance with Good Manufacturing Practice (GMP) guidelines. To obtain sufficient Treg for immunotherapy, subsequent ex vivo expansion might be needed.
Introduction
Regulatory T cells (Treg) play a critical role in various immunological processes, particularly in maintaining homeostasis and self-tolerance. Immunotherapy based on Treg infusion is therefore a potential treatment for many immune disorders. This approach has been proven successful in animal models of stem cell transplantation [1] [2] [3] [4] [5] [6] [7] , solid organ transplantation [8, 9] and autoimmunity [6, [10] [11] [12] [13] . Therapeutic application in humans requires large numbers of Treg, that have to be isolated and, if necessary, expanded using clinical grade (Good Manufacturing Practice, GMP) protocols. The CliniMACS system provides a relatively versatile method for GMP cell isolation and is able to manage large quantities of cells, for example from leukapheresis material.
Other authors have recently shown the feasibility of CliniMACS for CD4 pos CD25 high Treg enrichment, but failed to achieve Treg purity of more than 40-60% [14, 15] . For stem cell transplantation recipients, a suboptimal Treg purity is unlikely to be harmful. Currently, many stem cell transplantation recipients are treated with donor lymphocyte infusions to enhance graft-versus-leukemia/tumor responses. The main adverse effect of this treatment is graft-versus-host-disease (GVHD). The aim of Treg immunotherapy in this patient group is to reduce these graft-versus-host responses. Co-infusion of both non-regulatory T cells to ensure graft-versus-leukemia/tumor responses and Treg to prevent excessive GVHD is therefore a logical approach in this setting. However, in other patient groups, such as solid organ graft recipients and patients with auto-immune diseases, high purity of Treg for immunotherapy is crucial. Infusion of non-regulatory cells into patients that already suffer from unwanted immunological activity should be prevented, as these cells can potentially intensify the disease process. The main aggressive cell types in immune responses are cytotoxic CD8 pos T cells and CD4 pos conventional T cells, and contamination of CliniMACS isolated Treg populations with these cells should be avoided for immunotherapy in patients other than stem cell recipients. Likewise, contamination of the isolate with B cells could lead to the infusion of activated B cells with potential adverse immunological consequences. Although CliniMACS based Treg isolation from leukapheresis products will yield large numbers of Treg, ex vivo expansion of these cells prior to infusion might still be necessary to obtain sufficient numbers of Treg for effective immunotherapy. Treg can be expanded efficiently using polyclonal stimulation [16] [17] [18] [19] . However, antigen-specific Treg have been shown to be far more efficient than polyclonal Treg in animal models [3, [5] [6] [7] 12, 13] . In allogeneic transplantation, the target antigens are known (mainly foreign HLA) and human alloantigen-specific Treg can be obtained by expansion using stimulation with alloantigen [20, 21] .
For practical reasons, it would be convenient or even necessary to perform the leukapheresis procedure weeks/months before the transplantation or treatment and store the Treg until they are needed. Currently, information on cryopreservation of Treg is lacking.
In the current study, we confirm that GMP Treg isolation using standard CliniMACS procedures results in moderately pure Treg populations. Here, we show that purity of CliniMACS isolated Treg can be improved by depletion of CD127 pos cells. In addition, we show that CliniMACS isolated Treg can be expanded with maintenance of suppressive function using polyclonal or alloantigen stimuli in the presence of IL-2. Depletion of CD19 pos B cells during CliniMACS Treg isolation appears to be a prerequisite to prevent B cell outgrowth during expansion. Furthermore, we show that cryopreservation of Treg is feasible, but that the cells require activation to restore suppressive potential.
Results
Isolation of Treg using CliniMACS yields 40-60% pure CD4 pos CD25 high Treg populations with suppressive activity Treg immunotherapy will demand very high numbers of highly pure Treg populations isolated in a GMP manner. To obtain large numbers of Treg with optimal purity, we performed CD4 pos CD25 high T cell isolation from healthy donor leukapheresis products using the GMP CliniMACS system. The most straightforward strategy to enrich for Treg would be a one step positive selection of CD25 pos cells out of leukapheresis products. However, this strategy would unintentionally result in contaminating (activated) cytotoxic CD8 pos T cells in the isolated Treg populations. Therefore, our initial CliniMACS isolation strategy consisted of two steps: first a CD8 depletion step to exclude CD8 pos effector T cells from the isolated cell populations, followed by a CD25 enrichment step to enrich for CD4 pos CD25 high Treg (referred to as CliniMACS 8/25 ). For comparison, a laboratory scale MiniMACS based Treg isolation protocol was also performed (referred to as MiniMACS).
Leukapheresis products contained on average 3% CD4 pos CD25 high regulatory T cells ( Figure 1 and Figure 2B ). CliniMACS 8/25 and MiniMACS populations suppressed alloantigen driven responder T cell proliferation to a similar extent ( Figure 2C ). Notably, alloantigen expanded Treg populations showed higher suppressive capacity in alloantigen driven responder T cell responses as compared to polyclonally expanded Treg (.75% suppression at a Tresp:Treg ratio of 16:1 versus 50% suppression at Tresp:Treg ratios a Tresp:Treg ratio of 8:1, respectively, Figure 2C ). This indicates that the alloantigen expanded cell populations were enriched for alloantigen-specific Treg. As our group has shown previously, the low proliferation observed after addition of alloantigen expanded Tconv can be explained by distinct culture kinetics with an earlier proliferation peak and a net result of lower counts at day 5 [21] .
It would be convenient for Treg immunotherapy to be able to store Treg cells prior to manipulation and/or infusion. The suppressive capacity of cryopreserved CliniMACS Treg was impaired ( Figure 3 ), and could not be regained by cell resting for up to seven days in culture medium. However, expansion of cryopreserved CliniMACS cells restored suppressive capacity.
Depletion of CD19 pos cells during CliniMACS Treg isolation is necessary to prevent B cell contamination
After CliniMACS 8/25 isolation procedures, less than 3% B cells were present in isolated populations, these numbers increased after expansion to 5 to 10% ( Figure 4A ). In order to remove B cells from our CliniMACS isolated Treg populations, we tested the efficacy of CD19 pos B cell depletion in the CliniMACS isolation procedure.
In this strategy, first CD8 pos and CD19 pos cells were depleted, followed by enrichment of CD25 pos cells (referred to as CliniMACS 8/19/25 ). Less than 0.5% B cells were present after these isolations (see Table 1 and Figure 4B ) and no substantial B cell contaminations arose after either polyclonal or alloantigen expansion (see Table 2 and Figure 4B ). CliniMACS 8/19/25 populations were similar to CliniMACS 8/25 cells with respect to the phenotype, anergic state and suppressive potential, both directly after isolation as well as after expansion (data not shown). Thus, CD19 pos depletion effectively prevents B cell contaminations in CliniMACS Treg populations after isolation and after expansion.
Depletion of CD127 pos cells improves CliniMACS Treg purity

CD4
pos CD25 neg/low FoxP3 neg/low Tconv cells were the major contaminating cell type in CliniMACS isolated Treg (40-60% of the isolated populations, see Figure 1 ). Recently, it has been described that Tconv express the IL-7 receptor alpha-chain CD127, while Treg cells do not express CD127 [22, 23] . Indeed, CliniMACS isolated populations contained both CD127 neg and CD127 pos cells, reflecting the presence of both Treg and Tconv cells ( Figure 5A ). To improve the purity of Treg isolated with CliniMACS, we hypothesized that depletion of CD127 pos cells could be employed to exclude contaminating T cells. Because anti-CD127 CliniMACS beads are currently not available, we depleted CD127 pos cells from CliniMACS isolated cell populations by FACS.
As shown in Figure 5A , this procedure indeed enabled separation of Treg from Tconv cells. In contrast to CD127 pos cells, the majority of CliniMACS CD127 neg cells showed a Treg phenotype: CD4 pos CD25 high and FoxP3 pos . Since we used cryopreserved CliniMACS populations for these experiments, we expanded the populations prior to functional characterization. After expansion, CD127 neg populations retained a high Treg purity, as evidenced by high expression of CD25 and FoxP3 ( Figure 5B ). In contrast to CD127 pos populations, CD127 neg populations were anergic after expansion ( Figure 5C ). As expected, CD127 depletion enhanced suppressive potential, as shown by the significantly higher suppressive capacity of CD127 neg populations as compared to CliniMACS populations that were not depleted of CD127 pos cells ( Figure 5D ).
Discussion
Immunotherapy using ex vivo activated and/or expanded CD4 pos CD25 high regulatory T cells appears promising, not only in stem cell transplantation, but also for a number of autoimmune disorders. To be optimally effective, the availability of tailor-made clinical grade procedures is a prerequisite. As previously reported [14, 15] , CliniMACS GMP Treg isolation strategies based on CD25 pos enrichment typically result in 40-60% pure Treg with moderate suppressive activity.
The degree of purity of Treg that is required may depend on the actual application. In stem cell transplantation, the first clinical trials on Treg immunotherapy have recently been initiated. In these studies, either CliniMACS isolated CD4 pos CD25 high Treg (with 40-60% purity) or ex vivo manipulated CD4 pos T cell lines consisting of 5-10% induced regulatory Tr1 cells and consequently a substantial amount of non-Treg were infused in patients receiving stem cell transplantations [24] . So far, to our knowledge, no adverse effects have been reported. However, caution is necessary when applying Treg for auto-immune disease or solid organ transplant purposes. Here an inadvertently present effector pool might cause serious pathology.
As cytotoxic CD8 pos T cells are a potentially aggressive cell type in immune responses, it is highly recommendable to exclude these cells from CliniMACS isolated Treg populations. Here, we show that the CD8 pos CliniMACS cell depletion step was effective: less than 0.1% CD8 pos cells were present in isolated Treg populations, and no outgrowth of CD8 pos cells occurred after expansion of CliniMACS Treg populations. Treg isolated by CD25 pos enrichment following CD8 pos depletion contained a small contamination of B cells (1-3%), which could increase to up to 10% after T cell expansion. The risks of infusion of expanded and activated autologous B cells are unknown, but could in theory include the development of a B cell lymphoproliferative disorder that can occur after transplantation and is often lethal [25] [26] [27] . We were able to prevent the contamination by B cells by including a CD19 pos B cell depletion step in the isolation strategy. Notwithstanding the favorable effects of combined anti-CD25, anti-CD8 and anti-CD19 microbead isolation (the currently available clinical grade tools), the isolated Treg population was of suboptimal purity. Most of the contaminating cells appeared to be CD4 pos CD25
neg/low Tconv cells that could potentially lead to immunopathology. To further improve CliniMACS Treg purity, Wichlan et al. studied titration of anti-CD25 microbeads in the enrichment phase of CliniMACS Treg isolation. While the use of lower amounts of beads indeed led to populations with higher CD25 expression levels [15] , the suppressive capacity of the isolated populations did not improve and cell yields were significantly lower, indicating that titration of CD25 microbeads will not provide the solution to achieve higher purity for CliniMACS Treg isolation. These authors also reported that adjustment of CliniMACS flow rates did not lead to a higher Treg purity. Hoffmann et al. used three consecutive CliniMACS selection cycles for CD25 pos cells, to preferentially select CD25 high Treg and exclude CD25 neg/low Tconv [14] . However, the degree of Treg purity obtained with this approach was similar to that achieved with one CD25 enrichment cycle. Recently, it has been described that Tconv express the IL-7 receptor alpha chain CD127, while Treg do not express this molecule [22, 23] The outcome of a particular T cell based immune response is likely to be determined by the balance between the effector and regulatory T cell pools. Consequently, the efficacy of Treg therapy may be determined by the actual number of antigen reactive Treg within the infused cell population. Indeed, antigen-specific Treg were proven to be more efficient than polyclonal Treg in preclinical mouse models of autoimmunity [6, 12, 13] and graftversus-host disease [3, 5, 7] . Previously, we and others have shown that human Treg isolated by non-clinical grade strategies can be expanded using both polyclonal and alloantigen stimulation methods [16] [17] [18] [19] [20] [21] Clinical implementation of Treg based therapy will be highly facilitated if Treg can be stored prior to infusion, as this will allow a more flexible timing of Treg therapy and/or therapeutic schemes with multiple Treg treatments over time. We studied the feasibility of CliniMACS Treg cryopreservation in liquid nitrogen. Results indicate that Treg can survive cryopreservation, as thawed populations showed 70-80% cell viability. We noted decreased suppressive activity of thawed Treg populations, which could be restored by Treg expansion. An alternative approach would be to expand Treg prior to cryopreservation. This resulted in unaltered suppressive capacity upon thawing, at least in MiniMACS isolated Treg (Supplemental data, Figure S1 ).
In summary, we here provide further support for clinical implementation of Treg immunotherapy by showing that a high Treg purity can be reached, and that isolated cells can be cryopreserved and expanded successfully.
Materials and Methods
Human cells
Healthy donors were scheduled for leukapheresis procedures to obtain leukocytes for donor lymphocyte infusions in hematopoietic stem cell transplantation patients in the Radboud University Nijmegen Medical Centre. Excess leukapheresis material was used for the current study upon written informed consent with regard to scientific use. Buffy coats from healthy human donors were purchased from Sanquin bloodbank, Nijmegen, The Netherlands, upon written informed consent with regard to scientific use and used as a source of stimulator PBMC. The current study did not require approval from an ethics committee according to the Dutch Medical Research Involving Human Subjects Act.
Treg isolation
Healthy donor leukapheresis products were used for CliniMACS CD4 pos CD25 high Treg isolation. Cells were washed with PBS/EDTA buffer (Miltenyi Biotec, Bergisch-Gladbach, Germany, supplemented with 0.5% HSA (Sanquin bloodbank). Anti-CD8 and/or anti-CD19 coated CliniMACS microbeads (kindly provided by Miltenyi Biotec) were added, incubated for 30 minutes and washed. CliniMACS program 2.1 was run to deplete labeled cells (CliniMACS separation columns were kindly provided by Miltenyi Biotec). The labeling procedure was repeated with anti-CD25 CliniMACS microbeads, and Clini-MACS program 1.1 was run to enrich for CD25 pos cells. A non-GMP MiniMACS based CD4 pos CD25 high Treg isolation method was performed on leukocytes from the same leukapheresis products as used for CliniMACS Treg isolation. PBMC were alloantigen expansion) in the absence or presence of exogenous IL-2, measured at day 3 of culture. (C) Suppressive capacity in co-cultures of autologous naïve CD4 pos CD25 neg Tresp stimulated with allogeneic PBMC (same donor as in alloantigen expansion). Significant differences are indicated by asterisks. In figure C, isolated by density gradient centrifugation (Lymphoprep, Nycomed Pharma, Roskilde, Denmark). CD4 pos T cells were negatively selected using mAbs directed against CD8 (RPA-T8), CD14 (M5E2), CD16 (3G8), CD19 (4G7), CD33 (P67.6), CD235a (GA-R2(HIR2) (BD Biosciences, San Jose, CA, USA), and CD56 (MOC-1) (Dako, Glostrup, Denmark) combined with sheep-antimouse-IgG coated magnetic beads (Dynal Biotech, Oslo, Norway), routinely resulting in a .90% pure CD4 pos T cell fraction. CD25
high Treg and CD25 neg conventional T cells (referred to as Tconv, included in all experiments as control cell population) were separated by MACS-sorting, using 10 ml anti-CD25 magnetic microbeads/10 7 CD4 pos cells (Miltenyi Biotec). For CD127 pos cell depletion, CliniMACS isolated Treg were stained with anti-CD127-AlexaFluor647 (BD Biosciences) and CD127 pos cells were depleted on an Elite FACS machine (Beckman Coulter, Fullerton, CA, USA).
Stimulator PBMC were isolated from healthy donor buffy coat by density gradient centrifugation (Lymphoprep, Nycomed Pharma).
HLA typing was performed by serological and DNA based techniques according to international (ASHI/EFI) standards [28] .
Treg cryopreservation
Treg cells were suspended in RPMI 1640 supplemented with pyruvate (0,02 mM), penicillin (100 U/ml), streptomycin (100 mg/ ml), 20% human pooled serum (HPS) and 15% dimethylsulfoxide, were kept in 280uC for one week, and were subsequently transferred to liquid nitrogen for up to one year. Cells were quickly thawed in a 37uC water bath and washed twice before use.
Treg expansion
Cell cultures were performed in culture medium consisting of RPMI 1640 supplemented with pyruvate (0.02 mM), penicillin (100 U/ml), streptomycin (100 mg/ml), 10% HPS and IL-2 (25 U/ml, Chiron, Amsterdam, the Netherlands) with 5610 4 cells per well in 96-well round bottom plates, in a 37uC, 95% humidity, 5% CO 2 incubator. Stimulation was provided by either 10 5 irradiated (30 Gy) fully HLA-mismatched allogeneic PBMC per well (alloantigen expansion) or 1610 4 anti-CD3+anti-CD28 mAb coated microbeads per well (Dynal Biotech, polyclonal expansion).
Wells were split and provided with fresh medium containing cytokines every 3 days. After 10 days, the cells were harvested, washed and rested for 2 days in 5% HPS culture medium before functional and phenotypic analyses.
Flow cytometry
The phenotype of cells was analyzed by five-color flow cytometry (FC500, Beckman Coulter). For cell surface staining, the following conjugated mAbs were used: anti-CD4(SFCI12T4D11)-PCy7, anti-CD19(J4.119)-PE (Beckman Coulter), anti-CD25(4E3)-biotin, anti-biotin(Bio3-18E7)-PE (used in Figures 1 and 2 
Co-culture suppression assays
Statistical analysis
Proliferative capacities of different cell populations were compared using Student T tests. A P value,0.05 was considered statistically significant. Figure S1 Unaffected suppressive capacity of Mini-MACS Treg by expansion prior to cryopreservation. Suppressive capacity of cryopreserved MiniMACS Treg isolated from healthy donor buffy coat in co-cultures of autologous naïve CD4 pos CD25 neg Tresp stimulated with allogeneic PBMC. Data from one of two similar experiments are shown. Prior to co-culture suppression assay, indicated cell populations were expanded for 10 days in the presence of exogenous IL-2 and allogeneic PBMC (same donor as in co-culture suppression assay). Significant differences are indicated by asterisks. Open and filled asterisks refer to cryopreservation versus cryopreservation followed by expansion or expansion followed by cryopreservation, respectively. Found at: doi:10.1371/journal.pone.0003161.s001 (0.12 MB TIF)
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